Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the existence of gene mutations based on images of leukemia cells.
Clinical Trials Arena on MSN1d
Cantargia enrols first patient in trial of nadunolimab for AML and MDSSwedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
The Zinnia has been called ‘The hardest working flower,’ known to withstand tough conditions, and bloom anyways.
Caribou Biosciences (CRBU) reported better-than-expected earnings in the first quarter, with top and bottom-line beats. Despite this, the ...
Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...
Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...
Sutro Biopharma is undergoing a seismic shake-up —jettisoning its CEO, half of its workforce, its lead candidate and its ...
Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq ...
Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.
The combined use of two well-known active substances can fight leukemic cells and limit their spread. This is the result of a ...
Acute myeloid leukemia (AML) is a highly aggressive and difficult-to-treat blood cancer. This study explores the role of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback